The approval came days before the FDA’s expected deadline and makes this the only PD-1 inhibitor approved for resectable ...
The checkpoint inhibitor is now approved, based on CheckMate 77T findings, for neoadjuvant/adjuvant use in patients with ...
The FDA has approved Opdivo (nivolumab) as neoadjuvant and adjuvant treatment for adults with resectable NSCLC.
Opdivo (nivolumab) for resectable non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) ...
The FDA has approved nivolumab plus chemotherapy as a neoadjuvant treatment for operable stage IIA to IIIB non–small cell ...
No benefit seen for rechallenge with nivolumab after progression in the post-immune checkpoint inhibitor setting.
Medpage Today on MSN2d
De-Intensified Therapy Misses Mark in HPV-Positive Oropharyngeal CancerTwo strategies to de-escalate treatment for human papillomavirus (HPV)-positive oropharyngeal cancer failed to show ...
Nivolumab, given with or without ipilimumab, showed durable 10-year survival outcomes in patients with advanced melanoma.
During a Case-Based Roundtable® event, Laahn Foster, MD, discussed the 2024 update to the RELATIVITY-047 trial in advanced ...
Previous results from this trial showed longer overall survival after treatment with nivolumab plus ipilimumab or with nivolumab monotherapy than with ipilimumab monotherapy in patients with ...
Researchers compared health-related quality of life with nivolumab added to first-line chemo vs chemo alone in patients with ...
The approval was based on data from the randomized, double-blind, placebo-controlled, phase 3 CheckMate -77T trial.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback